Kura Oncology (KURA) Amortization of Deferred Charges (2016 - 2026)
Kura Oncology (KURA) reported Amortization of Deferred Charges of $106000.0 for Q1 2026, down 20.3% year-over-year from $133000.0 in Q1 2025, and up 2.91% on a QoQ basis from $103000.0 in Q4 2025.
Kura Oncology (KURA) has 7 years of Amortization of Deferred Charges data on file, last reported at $106000.0 in Q1 2026.
- Quarterly Amortization of Deferred Charges fell 20.3% year-over-year to $106000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $488000.0 (down 8.61% YoY) and the FY2025 annual result came in at $515000.0, down 1.53% from the prior year.
- Amortization of Deferred Charges advanced to $106000.0 in Q1 2026 per KURA's latest filing, from $103000.0 in the prior quarter.
- Across five years, Amortization of Deferred Charges topped out at $141000.0 in Q3 2025 and bottomed at $103000.0 in Q4 2025.
- The 4-year median for Amortization of Deferred Charges is $122000.0 (2023), against an average of $124692.3.
- The widest annual swing landed in 2024, when Amortization of Deferred Charges gained 17.65%; it then retreated 26.43% in 2025.
- Tracing KURA's Amortization of Deferred Charges over 4 years: stood at $119000.0 in 2023, then advanced by 17.65% to $140000.0 in 2024, then declined by 26.43% to $103000.0 in 2025, then gained by 2.91% to $106000.0 in 2026.
- Per Business Quant, the three latest KURA Amortization of Deferred Charges figures stand at $106000.0 (Q1 2026), $103000.0 (Q4 2025), and $141000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Kura Oncology | 801.92 Mn | 801.92 Mn | 18.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 106,000.00 |
| Mar 31, 2026 | 106,000.00 |
| Dec 31, 2025 | 103,000.00 |
| Dec 31, 2025 | 103,000.00 |
| Sep 30, 2025 | 141,000.00 |
| Sep 30, 2025 | 141,000.00 |
| Jun 30, 2025 | 138,000.00 |
| Jun 30, 2025 | 138,000.00 |
| Mar 31, 2025 | 133,000.00 |
| Mar 31, 2025 | 133,000.00 |
| Dec 31, 2024 | 140,000.00 |
| Dec 31, 2024 | 140,000.00 |
| Sep 30, 2024 | 134,000.00 |
| Sep 30, 2024 | 134,000.00 |
| Jun 30, 2024 | 127,000.00 |
| Jun 30, 2024 | 127,000.00 |
| Mar 31, 2024 | 122,000.00 |
| Mar 31, 2024 | 122,000.00 |
| Dec 31, 2023 | 119,000.00 |
| Dec 31, 2023 | 119,000.00 |
| Sep 30, 2023 | 122,000.00 |
| Sep 30, 2023 | 122,000.00 |
| Jun 30, 2023 | 121,000.00 |
| Jun 30, 2023 | 121,000.00 |
| Mar 31, 2023 | 115,000.00 |
| Mar 31, 2023 | 115,000.00 |
| Dec 31, 2018 | 17,000.00 |
| Dec 31, 2018 | 17,000.00 |
| Sep 30, 2018 | 53,000.00 |
| Sep 30, 2018 | 53,000.00 |
| Jun 30, 2018 | 57,000.00 |
| Jun 30, 2018 | 57,000.00 |
| Mar 31, 2018 | 57,000.00 |
| Mar 31, 2018 | 57,000.00 |
| Dec 31, 2017 | 56,000.00 |
| Dec 31, 2017 | 56,000.00 |
| Sep 30, 2017 | 30,000.00 |
| Sep 30, 2017 | 30,000.00 |
| Jun 30, 2017 | 16,000.00 |
| Jun 30, 2017 | 16,000.00 |
| Mar 31, 2017 | 16,000.00 |
| Mar 31, 2017 | 16,000.00 |
| Dec 31, 2016 | 15,000.00 |
| Dec 31, 2016 | 15,000.00 |
| Sep 30, 2016 | 16,000.00 |
| Sep 30, 2016 | 16,000.00 |